Co-reported respiratory adverse events in trastuzumab deruxtecan-associated interstitial lung disease: A pharmacovigilance analysis of the FAERS database - PubMed
3 hours ago
- #interstitial lung disease
- #trastuzumab deruxtecan
- #pharmacovigilance
- Trastuzumab deruxtecan (T-DXd) is linked to interstitial lung disease (ILD) and pneumonitis, but co-reported respiratory adverse events patterns are not well characterized.
- FAERS database analysis (2015-2025) identified 759 ILD and 289 pneumonitis cases involving T-DXd, using hierarchical clustering to examine co-reporting patterns.
- ILD clustered with dyspnea and cough in breast cancer, while in gastric/GEJ cancer, it co-reported with pneumonia, suggesting overlap with infectious presentations.
- Lung cancer reports showed heterogeneous respiratory co-reporting, with less consistent clustering of ILD with specific symptoms.
- ILD was a central node in the respiratory adverse event network, and clusters were stable across bootstrap analyses, indicating non-random patterns.
- Co-reported respiratory event patterns differ by tumor type, which may help clinicians interpret ILD reports in real-world practice.